Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil

New promising avenues for the pharmacological treatment of skeletal and heart muscle diseases rely on direct sarcomeric modulators, which are molecules that can directly bind to sarcomeric proteins and either inhibit or enhance their activity. A recent breakthrough has been the discovery of the myosin activator omecamtiv mecarbil (OM), which has been shown to increase the power output of the cardiac muscle and is currently in clinical trials for the treatment of heart failure. While the overall effect of OM on the mechano-chemical cycle of myosin is to increase the fraction of myosin molecules in the sarcomere that are strongly bound to actin, the molecular basis of its action is still not completely clear. We present here a Molecular Dynamics study of the motor domain of human cardiac myosin bound to OM, where the effects of the drug on the dynamical properties of the protein are investigated for the first time with atomistic resolution. We found that OM has a double effect on myosin dynamics, inducing a) an increased coupling of the motions of the converter and lever arm subdomains to the rest of the protein and b) a rewiring of the network of dynamic correlations, which produces preferential communication pathways between the OM binding site and distant functional regions. The location of the residues responsible for these effects suggests possible strategies for the future development of improved drugs and the targeting of specific cardiomyopathy-related mutations.

[1]  Andrij Baumketner,et al.  Early stages of the recovery stroke in myosin II studied by molecular dynamics simulations , 2011, Protein science : a publication of the Protein Society.

[2]  Yin-Biao Sun,et al.  Myosin light chain phosphorylation enhances contraction of heart muscle via structural changes in both thick and thin filaments , 2016, Proceedings of the National Academy of Sciences.

[3]  C. Gille,et al.  Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. , 2002, Biochemical and biophysical research communications.

[4]  I. Rayment,et al.  The structural basis of blebbistatin inhibition and specificity for myosin II , 2005, Nature Structural &Molecular Biology.

[5]  Francesca Fanelli,et al.  Wordom: A User-Friendly Program for the Analysis of Molecular Structures, Trajectories, and Free Energy Surfaces , 2010, J. Comput. Chem..

[6]  M. Gautel,et al.  Structure and Interactions of Myosin-binding Protein C Domain C0 , 2011, The Journal of Biological Chemistry.

[7]  Matteo Tiberti,et al.  xPyder: A PyMOL Plugin To Analyze Coupled Residues and Their Networks in Protein Structures , 2012, J. Chem. Inf. Model..

[8]  J. Spudich,et al.  Ensemble Force Changes that Result from Human Cardiac Myosin Mutations and a Small-Molecule Effector , 2015, Cell reports.

[9]  M. Karplus,et al.  Mechanical coupling in myosin V: a simulation study. , 2009, Journal of molecular biology.

[10]  F. Buss,et al.  Small-molecule inhibitors of myosin proteins. , 2013, Future medicinal chemistry.

[11]  J. Spudich,et al.  Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases , 2014, Biophysical journal.

[12]  Christine E. Seidman,et al.  A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice , 2016, Science.

[13]  C. Cohen,et al.  Rigor-like structures from muscle myosins reveal key mechanical elements in the transduction pathways of this allosteric motor. , 2007, Structure.

[14]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[15]  Iain M. Wallace,et al.  M-Coffee: combining multiple sequence alignment methods with T-Coffee , 2006, Nucleic acids research.

[16]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[17]  Haibo Yu,et al.  Mechanochemical Coupling in the Myosin Motor Domain. I. Insights from Equilibrium Active-Site Simulations , 2006, PLoS Comput. Biol..

[18]  V. J. Planelles-Herrero,et al.  Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil , 2017, Nature Communications.

[19]  R. Dror,et al.  Systematic Validation of Protein Force Fields against Experimental Data , 2012, PloS one.

[20]  Joseph L. Baker,et al.  Effects of ATP and actin-filament binding on the dynamics of the myosin II S1 domain. , 2013, Biophysical journal.

[21]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[22]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[23]  H. Woo.  Exploration of the conformational space of myosin recovery stroke via molecular dynamics. , 2007, Biophysical chemistry.

[24]  Wim F Vranken,et al.  ACPYPE - AnteChamber PYthon Parser interfacE , 2012, BMC Research Notes.

[25]  S. Fischer,et al.  Structural mechanism of the ATP-induced dissociation of rigor myosin from actin , 2011, Proceedings of the National Academy of Sciences.

[26]  Carsten Kutzner,et al.  Tackling Exascale Software Challenges in Molecular Dynamics Simulations with GROMACS , 2015, EASC.

[27]  Alessandro Pandini,et al.  GSATools: analysis of allosteric communication and functional local motions using a structural alphabet , 2013, Bioinform..

[28]  Serena Sirigu,et al.  How actin initiates the motor activity of Myosin. , 2015, Developmental cell.

[29]  Andrea Amadei,et al.  Essential dynamics: foundation and applications , 2012 .

[30]  B. Greenberg,et al.  Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. , 2015, JACC. Heart failure.

[31]  Alessandro Pandini,et al.  Structural alphabets derived from attractors in conformational space , 2010, BMC Bioinformatics.

[32]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[33]  Yuan Zhang,et al.  Identifying Highly Conserved and Unique Structural Elements in Myosin VI , 2012 .

[34]  Yingying Liu,et al.  Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin. , 2015, Biochemistry.

[35]  Kenneth C Holmes,et al.  The actin-myosin interface , 2010, Proceedings of the National Academy of Sciences.

[36]  Wenjun Zheng,et al.  All-atom molecular dynamics simulations of actin-myosin interactions: a comparative study of cardiac α myosin, β myosin, and fast skeletal muscle myosin. , 2013, Biochemistry.

[37]  Michael D. Daily,et al.  Allosteric activation transitions in enzymes and biomolecular motors: insights from atomistic and coarse-grained simulations. , 2013, Topics in current chemistry.

[38]  P. Trotta,et al.  Myosin , 1967, The Journal of General Physiology.

[39]  Stefan Fischer,et al.  The structural coupling between ATPase activation and recovery stroke in the myosin II motor. , 2007, Structure.

[40]  M. Karplus,et al.  Pi release from myosin: a simulation analysis of possible pathways. , 2010, Structure.

[41]  A. Pandini,et al.  Detection of allosteric signal transmission by information-theoretic analysis of protein dynamics , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  V. Daggett,et al.  Molecular mechanisms underlying deoxy‐ADP.Pi activation of pre‐powerstroke myosin , 2017, Protein science : a publication of the Protein Society.

[43]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[44]  W. Taylor,et al.  The Phylogenetic Signature Underlying ATP Synthase c-Ring Compliance , 2015, Biophysical journal.

[45]  Ann M Stock,et al.  Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity , 2015, Nature Communications.

[46]  P. Nanasi,et al.  The myosin activator omecamtiv mecarbil: a promising new inotropic agent. , 2016, Canadian journal of physiology and pharmacology.

[47]  R. Elber,et al.  Atomically detailed simulation of the recovery stroke in myosin by Milestoning , 2010, Proceedings of the National Academy of Sciences.

[48]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[49]  D. Manstein,et al.  Myosin structure, allostery, and mechano-chemistry. , 2013, Structure.

[50]  Andrew C. R. Martin,et al.  The structural effects of mutations can aid in differential phenotype prediction of beta-myosin heavy chain (Myosin-7) missense variants , 2016, Bioinform..

[51]  Brian D. Sykes,et al.  Targeting the sarcomere to correct muscle function , 2015, Nature Reviews Drug Discovery.

[52]  Anne Houdusse,et al.  Structural and functional insights into the Myosin motor mechanism. , 2010, Annual review of biophysics.

[53]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[54]  P. Charron,et al.  Mutation Screening in Dilated Cardiomyopathy: Prominent Role of the Beta Myosin Heavy Chain Gene , 2005 .

[55]  Alessandro Pandini,et al.  Using Local States To Drive the Sampling of Global Conformations in Proteins , 2016, Journal of chemical theory and computation.

[56]  Piotr Ponikowski,et al.  Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial , 2016, The Lancet.

[57]  V. J. Planelles-Herrero,et al.  Highly selective inhibition of myosin motors provides the basis of potential therapeutic application , 2016, Proceedings of the National Academy of Sciences.

[58]  Piotr Ponikowski,et al.  Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. , 2016, Journal of the American College of Cardiology.

[59]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[60]  C. D. dos Remedios,et al.  Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. , 2015, Journal of molecular and cellular cardiology.

[61]  J. Teerlink,et al.  Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. , 2017, Handbook of experimental pharmacology.

[62]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[63]  Yin-Biao Sun,et al.  Novel myosin-based therapies for congenital cardiac and skeletal myopathies , 2016, Journal of Medical Genetics.

[64]  X. Daura,et al.  Peptide Folding: When Simulation Meets Experiment , 1999 .

[65]  Steven Hayward,et al.  A method for the analysis of domain movements in large biomolecular complexes , 2009, Proteins.

[66]  A. Fornili,et al.  Energy landscapes associated with macromolecular conformational changes from endpoint structures. , 2010, Journal of the American Chemical Society.

[67]  J. Goldman,et al.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study , 2011, The Lancet.

[68]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[69]  D. Manstein,et al.  Small molecule-mediated refolding and activation of myosin motor function , 2014, eLife.

[70]  Stefan Fischer,et al.  Structural mechanism of the recovery stroke in the myosin molecular motor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Joseph M. Muretta,et al.  Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke , 2017, Proceedings of the National Academy of Sciences.

[72]  Matteo Tiberti,et al.  (Dis)similarity Index To Compare Correlated Motions in Molecular Simulations. , 2015, Journal of chemical theory and computation.

[73]  O Jardetzky,et al.  Protein dynamics. , 1994, FEBS letters.

[74]  Haibo Yu,et al.  Mechanochemical Coupling in the Myosin Motor Domain. II. Analysis of Critical Residues , 2007, PLoS Comput. Biol..

[75]  Mark Newman,et al.  Networks: An Introduction , 2010 .

[76]  Kenneth C Holmes,et al.  The molecular mechanism of muscle contraction. , 2005, Advances in protein chemistry.

[77]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.